

News Release
For Immediate Release

OE signs agreement with Medinox to develop a new antihypotensive drug

Taipei, Taiwan, April 6, 2010 – Orient Europharma Co. Ltd. (OE, Taiwan OTC: 4120) today announced it has signed an agreement with US pharmaceutical company Medinox to develop and market new anti-hypotensive drug NOX-100.

Under the terms of the agreement, OE holds the exclusive distribution rights of NOX-100 in Taiwan, China, Korea, Australia, New Zealand and Southeast Asia. Medinox retains the marketing rights in the United States, Japan and Europe.

NOX-100 is an investigative new drug developed by Medinox to treat conditions associated with excessive production of nitric oxide, such as in hemodialysis, septic shock, trauma and burn. It is the first drug to reduce the occurrence of hypotension, or low blood pressure, which is a common complication during dialysis.

According to the latest global rankings, Taiwan's rate of dialysis ranked number one in the world in the last eight consecutive years. The implementation of Taiwan's national health insurance program has increased the quality of medical treatment in the country, and made dialysis more accessible to patients. Statistics by Taiwan's Department of Health indicate that renal diseases are the seventh leading cause of death in the country, while the number of patients continues to increase. Over 90 percent of renal disease patients choose hemodialysis as their preferred treatment.

Intradialytic hypotension (IH) is a significant complication of routine hemodialysis in end-stage renal disease patients. Complications of IH include headache, muscle cramps, and increase in mortalities. At present, there is no FDA-approved therapy available for treating and/or preventing IH. NOX-100, if administered before hemodialysis, could help reduce the side effects associated with IH and increase treatment efficacy. In Taiwan, there are about 60,000 patients currently undergoing dialysis, and the number increases by an average of 20 daily. Of these, about 10,800 to 16,200 patients could benefit from using NOX-100.

Medinox completed a phase 1 safety study of NOX-100 in hemodialysis patients in the United States. A phase 2 trial of NOX-100 in hemodialysis will be conducted in Taiwan. This multicenter study is intended to determine that NOX-100 lowers the incidence of IH, decreases the frequency of nurse intervention, and reduces the number of patient complaints and discomfort. The introduction of this drug will increase the treatment quality and effectiveness for hemodialysis patients.

#

About Medinox, Inc.

Medinox is a leader in anti-NO therapeutics and is developing a broad technology platform to address a wide variety of unmet medical needs including hemodialysis, septic chock, trauma and burn. In addition to its NO technology, Medinox is also developing new and safer NSAID prodrugs for treating arthritic patients. For information about Medinox and its products, please visit the company's Web site at <http://www.medinox.com/>, or contact Dr. Monte Lai, president and CEO of Medinox Inc., at cslai@medinox.com.

About Orient Europharma Co. Ltd.

Founded in 1982, Orient Europharma (OE, Taiwan OTC: 4120) comprises five divisions: Pharma, Nutricare, Dermo-Cosmetics, Oncology and Consumer Healthcare. Starting in 1993, OE established subsidiaries in Singapore, Hong Kong, Malaysia, and the Philippines. In 2006, OE expanded into mainland China. In 2003, the company listed on Taiwan's OTC market. In 2008, OE established a subsidiary Orient Pharma (OP), to focus on new drug R&D and manufacturing operations. OP is building a new pharmaceutical manufacturing facility in the Central Taiwan Science Park in Yunlin, which is designed to comply with the international standards of the USFDA, as well as European PIC/S and Japanese certification bodies. The current proprietary technologies of OP include a two-stage hot melt filling technology platform and development of new drugs for several therapeutic areas. More information on OE can be found in the company's Web site: <http://www.oep.com.tw/>